Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients

Table 2 Comparison of serum inflammatory factors between the two groups (${\overline{\text{x}}} \pm {\text{s}}$)

	Experimental group (n = 65)			Control group (n = 65)			t#	P# value	T$	P^$ value
	Before treatment	After treatment	Difference between before and after treatment	Before treatment	After treatment	Difference between before and after treatment	t#	P# value	T$	P^$ value
IL-6 (ng·L-1)	172.09 ± 15.29	90.01 ± 8.02*	82.08 ± 7.27	171.89 ± 16.21	101.27 ± 7.27*	70.62 ± 8.94	− 8.386	< 0.001	8.018	< 0.001
IL-8 (ng·L-1)	269.08 ± 12.09	152.63 ± 18.72*	116.45 ± 6.63	268.91 ± 11.78	160.92 ± 12.29*	107.99 ± 0.51	− 2.985	.003	10.257	< 0.001
Hs-CRP (ng·L-1)	74.82 ± 5.29	6.83 ± 1.01*	67.99 ± 4.28	74.21 ± 5.21	9.21 ± 0.76*	65.00 ± 4.45	− 15.180	< 0.001	3.904	< 0.001
TNF-α (ng·L-1)	108.93 ± 9.03	61.87 ± 6.38*	47.06 ± 2.65	108.27 ± 8.92	68.29 ± 7.11*	39.98 ± 1.81	− 5.418	< 0.001	17.787	< 0.001

IL, interleukin; Hs-CRP, high-sensitivity C-reactive protein; TNF, tumor necrosis factor
^*Compared with that of before treatment, P < 0.001
^#Comparisons between experimental group and control group after treatment
^$Comparisons of difference in the values before and after treatment between the two groups

ISSN: 1471-230X